Introduction
Primary or AL amyloidosis is the most common and most aggressive form of systemic amyloidosis. 1 In this form of amyloidosis, a plasma cell dyscrasia results in the production of monoclonal Ig light chains that form fibrils and are amyloidogenic. The accumulation of amyloid deposits in the heart, kidneys, liver, gastrointestinal tract, autonomic nervous system and soft tissues leads to progressive disability, organ failure and death. 2 Treatment for AL amyloidosis is based on the observation that organ function improves and survival increases when the synthesis of amyloidogenic precursor protein is halted. Therapeutic measures are, therefore focused toward reducing amyloidogenic monoclonal light chain production by attacking the underlying plasma cell dyscrasia. Highdose melphalan (HDM) followed by autologous peripheral SCT, is an effective method of accomplishing this. The results of single-center and multicenter studies of HDM/ SCT are encouraging, with hematologic complete response (HCR) rates, that is, disappearance of the underlying plasma cell dyscrasia, of 25-67% being reported. 3 Patients who achieve an HCR have a median survival of 48 years compared with 5.2 years for those who do not. In addition, clinical improvement in affected organ systems occurs in 2/3 of patients who achieve an HCR compared with only 1/3 of those who do not. Improvement in performance status and quality of life also seems to be dependent on hematological response to treatment. 4 On the basis of these observations, we conducted a prospective trial of tandem cycles of HDM/SCT for the treatment of AL amyloidosis, following on the successful results of this approach in multiple myeloma. We found that treatment with tandem cycles of HDM/SCT is feasible and tolerable for selected patients with AL amyloidosis. This treatment also increased the proportion of patients who ultimately achieved an HCR and seems, at early analysis, to be associated with an improvement in overall survival. 5 To date, 57 patients have been treated with tandem cycles of HDM/SCT at Boston University Medical Center. A total of 11 of those patients experienced an unexpected, treatment-related adverse event that we describe as a 'melphalan recall' reaction. This reaction consists of a culture-negative fever, at times accompanied by hypotension, rash or flushing, that occurs shortly after the second cycle of melphalan administration, as described in this case series.
Methods
Data on patients undergoing treatment for AL amyloidosis were collected with the permission of the Institutional Review Board. From August 1994 to July 2008, 410 patients underwent treatment with HDM/SCT. A total of 57 of those patients were treated with a second cycle of HDM/SCT during this same time period because of persistence of plasma cell dyscrasia after the first cycle of HDM/SCT. In total, 3 of those 57 patients had their first transplant carried out at a facility other than Boston Medical Center. A total of 11 patients developed a febrile reaction shortly after melphalan infusion during their second cycle of treatment and form the study population for characterization of this syndrome. No patient had such a reaction during the first cycle of treatment. The medical records of the patients who developed this clinical syndrome were reviewed retrospectively. Serial cytokine measurements were obtained for one patient using our earlier described multiplex cytokine immunoassay. 6 
Results
A total of 11 out of 57 patients treated with tandem cycles of HDM/SCT developed a febrile syndrome shortly after the second cycle of chemotherapy administration and are presented in Table 1 . Most of the patients were treated within 1 year of their first transplant, however, two patients had their second transplants much later; one was 4 years and 9 months after the first transplant and another was just over 5 years after the first treatment. There were seven male and four female patients, with an average age of 53.5 years. All patients had a diagnosis of AL amyloidosis with a lambda clonal plasma cell dyscrasia except one who had a kappa clonal plasma cell dyscrasia. All patients experiencing this syndrome developed fever within 12-24 h of receiving the first dose of melphalan in preparation for a second transplant. All patients had a tunneled central venous catheter placed before melphalan infusion. There was an average delay of 4 days from the time of line placement to onset of fever. Peak oral temperatures ranged from 38.1 1C (100.6 1F) to as high as 39.6 1C (103.2 1F), with an average high temperature of 38.9 1C (102.03 1F) and median temperature of 39.1 1C (102.3 1F). The median peak WBC in all patients who experienced this reaction was 11.4 K/ul with a range of 7.7-24.9 K/ul. The median percentage of bands was 30% with a range of 11-48%. All 57 patients received 10 mg of dexamethasone orally before melphalan administration for prophylaxis against emesis. Four patients became hemodynamically unstable with hypotension. One patient required pressors to maintain adequate tissue perfusion, whereas the others responded to i.v. fluids alone. All patients were thoroughly evaluated for the source of fever, including blood and urine cultures, as well as a chest X-ray. One patient had a positive urine culture for Enterococcus, and another had one of four blood cultures that returned positive for coagulase-negative Staphylococcus species. This was thought to be a contaminant. The remaining patients were entirely culture negative.
All patients diagnosed with this febrile reaction were admitted to the hospital for observation and management. Two patients were admitted to the intensive care unit for close monitoring. Although this reaction is serious and requires hospitalization with close observation and supportive care, no delays in treatment occurred secondary to the reaction, and all patients completed the transplantation as scheduled.
Serum was available for cytokine evaluation from a single patient who experienced this syndrome. Available samples had been collected 2 years before the second transplant at an initial evaluation, on day 1 of chemotherapy for the second transplant (day À3 of transplant course) and on the two subsequent days (days À2 and À1 of treatment). Reinfusion of the patient's stem cells occurred as scheduled on day 0. Levels of IL-1ra, hIL-1R2, hIL4, hIL6, hIL6R hIL8, hIL10, hIL12, hGROa, hIFNy, MCP-1, MIP-1a, MIP-1B, TNFSRi, hTNFSRII, hTNFa and hIL-1B were measured. There was a 10-fold increase in IL-6, a classic pro-inflammatory cytokine. Levels of other pro-inflammatory cytokines, including hMCP1, hMIP1Beta and TNF-a, increased 14-, 10-and 10-fold, respectively (see Table 2 ). In addition, several anti-inflammatory cytokines increased in concentration during the reaction (see Table 3 ). Other cytokines measured were either undetectable or showed no significant change in concentration during the reaction described. The trend in serum levels of pro-inflammatory and anti-inflammatory cytokines are shown graphically in Figures 1 and 2 , respectively. All 11 patients diagnosed with this syndrome did not differ significantly from the other 46 patients treated with tandem cycles of HDM/SCT at Boston Medical Center with regard to age, gender, disease-related organ involvement or monoclonal light chain predominance. There was also no significant difference between those who developed the reaction and those who did not with regard to timing of line placement, pre-medication given or empiric antibiotic management. A total of 4 of the 11 patients obtained a HCR after the second transplant, similar to the rate of response in patients not experiencing this syndrome. All but one of the patients with the 'melphalan recall' reaction was alive at the time of this report.
Discussion
The 'melphalan recall reaction' was first noted by our group in a report of a clinical trial using tandem cycles of high-dose melphalan and autologous stem cell transplant to treat patients with AL amyloidosis. 5 In this report, 6 out of 17 patients treated with a second transplant were reported to have developed a febrile reaction 12-24 h after the first day of melphalan treatment. Fevers persisted for up to 48 h with no positive-cultures obtained. Here, we describe an additional 5 patients out of 57 total patients treated with a second course of high-dose melphalan and autologous stem cell transplant, who had a similar reaction, and provide additional clinical and molecular characterization of the syndrome. When evaluating all 57 patients treated with tandem courses of HDM/SCT, there are no significant differences between those who developed this febrile reaction and those who did not with regard plasma cell burden, monoclonal light chain type or organ involvement. Pg/mL hMCP1 Pg/mL hMIP1b Pg/mL Figure 1 Pro-inflammatory cytokines.
All patients with 'melphalan recall' reaction developed a remarkable leukocytosis and bandemia. Although these patients were pre-medicated with dexamethasone before melphalan administration, so were all of the patients treated with HDM/SCT; only patients diagnosed with the 'melphalan recall' developed such a significant bandemia in the absence of infection.
The etiology of this reaction seems to be due to a cytokine-mediated response rather than to an infectious etiology. Two patients had positive culture, but one was a urinary pathogen without any evidence for urosepsis and the other seems to have been a contaminant. Cytokines measured from the final patient reported revealed elevated levels of classic pro-inflammatory and anti-inflammatory cytokines.
Cytokines are involved in the induction and regulation of immune, inflammatory and hematopoietic processes. 7 Known pyrogenic cytokines that cause fever include IL-1, IL-6, TNF ciliary neurotrophic factor and IFN-a. The synthesis and release of endogenous pyrogens is induced by a variety of exogenous factors, most of which are infectious in etiology. However, in the absence of infection, inflammation, trauma, tissue necrosis or antigen-antibody complexes can induce the release of pro-inflammatory cytokines. In this syndrome, the precipitant for cytokine release is unclear.
Other types of febrile reactions have been attributed to cytokine release. The Jarisch-Herxheimer Reaction is a transient reaction occurring soon after the first adequate dose of a drug, usually an antibiotic, which includes, fever, sweats, anorexia and rash. The rise in temperature and other symptoms have been shown to correlate with an elevation of pro-inflammatory cytokines, including IL-6, IL-8 and TNF-a. 8 Perhaps the melphalan recall reaction occurs through a similar mechanism.
Cytokine networks may be disturbed in some patients with plasma cell diseases. 10 Serum levels of IL-6 are increased in patients with multiple myeloma and high levels reflect disease severity. 11 Notably, fever has been reported in two patients with multiple myeloma, associated with elevation of LDH, CRP and IL-6. 12 Perhaps, patients with AL amyloidosis share a similar cytokine milieu to patients with multiple myeloma with an imbalance that presents clinically during specific treatment scenarios. It is important to note, however, that this reaction has not been reported in patients with multiple myeloma treated with tandem courses of HDM/SCT. Equally critical is that, although a surge in cytokines has been noted in a single patient experiencing a febrile, systemic reaction, it is not known whether a similar cytokine storm occurred in any of the other patients who experienced the 'melphalan recall' reaction. Likewise, it is not known whether other patients with AL amyloidosis share a similarly elevated cytokine profile independent of having had the 'melphalan recall' reaction.
Although the etiology is unclear, clinicians should be aware of this phenomenon termed a 'melphalan recall' reaction in patients with AL amyloidosis treated with tandem cycles of HDM/SCT. Also unclear are the risk factors for this reaction as well as preventative strategies. However, we have documented a physiological cytokine response in one of the patients reported. This cytokine response is similar to that reported in other non-infectious febrile reactions, including the Jarisch-Herxheimer Reaction, drug-induced SIRS and multiple myeloma. Further studies on cytokine levels and inflammatory markers will be conducted in patients with AL amyloidosis in the future to better define the etiology of this reaction.
